Publications by authors named "Rachel Brault"
Article Synopsis
- The study aims to evaluate how native joint septic arthritis (NJSA) is managed and the outcomes for patients in various rheumatology departments across France, covering cases from 2016 to 2017.
- A total of 362 NJSA patients were analyzed, revealing that knee involvement is common and that Staphylococcus aureus is the leading pathogen; treatment varied and included prolonged antibiotic use, surgeries, and challenges related to complications and mortality.
- The findings underscore a grim prognosis for NJSA, with significant morbidity and mortality rates, emphasizing the necessity for standardized management practices as outlined in new French guidelines released post-study.
Article Synopsis
- - The study investigates the diagnosis and treatment outcomes of multidrug-resistant osteoarticular tuberculosis (MDR-OATB) in France, based on a review of 23 cases from 2007 to 2018.
- - Most affected patients were young males, with the spine being the most common site of infection; a significant portion had prior tuberculosis treatments.
- - Despite a high treatment success rate (91%) achieved with a mean regimen of four drugs over approximately 20 months, the ideal treatment protocol for MDR-OATB, including drug combinations and surgical options, is still not established.
The management of multiple myeloma has benefited substantially from the introduction of three new drugs, namely, the proteasome inhibitor bortezomib and the immunomodulators thalidomide and lenalidomide. These drugs were initially shown to improve the outcome of advanced myeloma and were subsequently found to transform the treatment of patients with previously untreated myeloma. Melphalan and prednisone combined with thalidomide or bortezomib is the new treatment of reference for patients who are elderly or ineligible for intensification.
View Article and Find Full Text PDFBackground: Chronic hepatitis C infection is frequently associated with a mixed cryoglobulinaemia and circulating auto-antibodies, especially anti-smooth muscle cells (SMA) and anti-liver/kidney/microsome type 1 (LKM-1) anti-tissue antibodies. Treatments with TNF antagonists favour the emergence of auto-antibodies, and particularly anti-dsDNA antibodies.
Objective: To determine the impact of TNF antagonists on hepatitis C-related immune abnormalities.